Clinical Trial Update: Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity [Phase 1]

View source ↗

Summary

This Phase 1 trial update, sponsored by Amgen, is designed to assess whether Maridebart Cafraglutide affects the pharmacokinetics of oral contraceptives in post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• Maridebart Cafraglutide

Snippet

Sponsor: Amgen | Conditions: Overweight, Obesity | Phase 1 | Status: NOT_YET_RECRUITING